Related Experiment Videos
AE-941 (Neovastat): a novel multifunctional antiangiogenic compound
D Gingras1, G Batist, R Béliveau
1Laboratiore de médicine moléculaire Hôpital Ste-Justine-UQAM, Centre de cancérologie Charles-Bruneau, Centre de Recherche de l'Hôpital Ste-Justine, 3175, Chemin Côte-Ste-Catherine, Montréal, Québec H3T 1C5, Canada.
Expert Review of Anticancer Therapy
|July 13, 2002
Summary
AE-941 (Neovastat), an antiangiogenic drug derived from cartilage, shows promise in treating solid tumors. Clinical trials indicate it improves survival times in patients with renal cell carcinoma and non-small cell lung cancer.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- AE-941 (Neovastat) is a naturally occurring product from cartilage with demonstrated antiangiogenic properties.
- It is under investigation for solid tumor treatment, including non-small cell lung cancer and renal cell carcinoma, with ongoing trials in multiple myeloma.
Purpose of the Study:
- To evaluate the efficacy and safety of AE-941 as an antiangiogenic therapeutic agent.
- To assess the impact of AE-941 on angiogenesis pathways and patient survival in clinical trials.
Main Methods:
- AE-941 was administered orally in Phase I/II clinical trials.
- Mechanisms investigated include inhibition of matrix metalloproteinases, VEGF signaling, induction of endothelial cell apoptosis, and tissue-type plasminogen activator activity.
Main Results:
- AE-941 was well tolerated in Phase I/II clinical trials.
- Significant improvements in median survival time were observed in patients with renal cell carcinoma and non-small cell lung cancer receiving high doses of AE-941 compared to low doses.
Conclusions:
- AE-941 is a multifunctional antiangiogenic drug with a favorable safety profile.
- The findings support AE-941's potential as an effective treatment for angiogenesis-dependent solid tumors, warranting further clinical evaluation.